tetano
Editor, Senior Moderator
Clin Appl Thromb Hemost
. 2022 Jan-Dec;28:10760296221131802.
doi: 10.1177/10760296221131802.
In-hospital Mortality Rates in SARS-CoV-2 Patients Treated with Enoxaparin and Heparin
Moudhi Alroomi[SUP] 1 [/SUP], Ahmad Alsaber[SUP] 2 [/SUP], Bader Al-Bader[SUP] 3 [/SUP], Farah Almutairi[SUP] 3 [/SUP], Haya Malhas[SUP] 4 [/SUP], Jiazhu Pan[SUP] 2 [/SUP], Kobalava D Zhanna[SUP] 5 [/SUP], Maryam Ramadhan[SUP] 6 [/SUP], Mohammad Al Saleh[SUP] 3 [/SUP], Mohammed Abdullah[SUP] 1 [/SUP], Naser Alotaibi[SUP] 7 [/SUP], Noor AlNasrallah[SUP] 7 [/SUP], Rajesh Rajan[SUP] 8 [/SUP], Soumoud Hussein[SUP] 9 [/SUP], Wael Aboelhassan[SUP] 10 [/SUP]
Affiliations
Abstract
Objectives: This study aimed to investigate in-hospital mortality rates in patients with coronavirus disease (COVID-19) according to enoxaparin and heparin use.
Methods: This retrospective cohort study included 962 patients admitted to two hospitals in Kuwait with a confirmed diagnosis of COVID-19. Cumulative all-cause mortality rate was the primary outcome.
Results: A total of 302 patients (males, 196 [64.9%]; mean age, 57.2 ± 14.6 years; mean body mass index, 29.8 ± 6.5 kg/m[SUP]2[/SUP]) received anticoagulation therapy. Patients receiving anticoagulation treatment tended to have pneumonia (n = 275 [91.1%]) or acute respiratory distress syndrome (n = 106 [35.1%]), and high D-dimer levels (median [interquartile range]: 608 [523;707] ng/mL). The mortality rate in this group was high (n = 63 [20.9%]). Multivariable logistic regression, the Cox proportional hazards, and Kaplan-Meier models revealed that the use of therapeutic anticoagulation agents affected the risk of all-cause cumulative mortality.
Conclusion: Age, hypertension, pneumonia, therapeutic anticoagulation, and methylprednisolone use were found to be strong predictors of in-hospital mortality. In elderly hypertensive COVID-19 patients on therapeutic anticoagulation were found to have 2.3 times higher risk of in-hospital mortality. All cause in-hospital mortality rate in the therapeutic anticoagulation group was up to 21%.
Keywords: COVID-19; SARS-CoV-2; anticoagulation; in-hospital mortality; pneumonia.
. 2022 Jan-Dec;28:10760296221131802.
doi: 10.1177/10760296221131802.
In-hospital Mortality Rates in SARS-CoV-2 Patients Treated with Enoxaparin and Heparin
Moudhi Alroomi[SUP] 1 [/SUP], Ahmad Alsaber[SUP] 2 [/SUP], Bader Al-Bader[SUP] 3 [/SUP], Farah Almutairi[SUP] 3 [/SUP], Haya Malhas[SUP] 4 [/SUP], Jiazhu Pan[SUP] 2 [/SUP], Kobalava D Zhanna[SUP] 5 [/SUP], Maryam Ramadhan[SUP] 6 [/SUP], Mohammad Al Saleh[SUP] 3 [/SUP], Mohammed Abdullah[SUP] 1 [/SUP], Naser Alotaibi[SUP] 7 [/SUP], Noor AlNasrallah[SUP] 7 [/SUP], Rajesh Rajan[SUP] 8 [/SUP], Soumoud Hussein[SUP] 9 [/SUP], Wael Aboelhassan[SUP] 10 [/SUP]
Affiliations
- PMID: 36285386
- DOI: 10.1177/10760296221131802
Abstract
Objectives: This study aimed to investigate in-hospital mortality rates in patients with coronavirus disease (COVID-19) according to enoxaparin and heparin use.
Methods: This retrospective cohort study included 962 patients admitted to two hospitals in Kuwait with a confirmed diagnosis of COVID-19. Cumulative all-cause mortality rate was the primary outcome.
Results: A total of 302 patients (males, 196 [64.9%]; mean age, 57.2 ± 14.6 years; mean body mass index, 29.8 ± 6.5 kg/m[SUP]2[/SUP]) received anticoagulation therapy. Patients receiving anticoagulation treatment tended to have pneumonia (n = 275 [91.1%]) or acute respiratory distress syndrome (n = 106 [35.1%]), and high D-dimer levels (median [interquartile range]: 608 [523;707] ng/mL). The mortality rate in this group was high (n = 63 [20.9%]). Multivariable logistic regression, the Cox proportional hazards, and Kaplan-Meier models revealed that the use of therapeutic anticoagulation agents affected the risk of all-cause cumulative mortality.
Conclusion: Age, hypertension, pneumonia, therapeutic anticoagulation, and methylprednisolone use were found to be strong predictors of in-hospital mortality. In elderly hypertensive COVID-19 patients on therapeutic anticoagulation were found to have 2.3 times higher risk of in-hospital mortality. All cause in-hospital mortality rate in the therapeutic anticoagulation group was up to 21%.
Keywords: COVID-19; SARS-CoV-2; anticoagulation; in-hospital mortality; pneumonia.